艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

交易中 11-22 12:07:34 EST

77.01

-0.11

-0.14%

最高77.50	最低76.81	成交量14.11万
今开77.49	昨收77.12	日振幅0.89%
总市值83.94亿	流通市值82.40亿	总股本1.09亿
成交额1,088万	换手率0.13%	流通股本1.07亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":77.01,"timestamp":1732295252649,"preClose":77.12,"halted":0,"volume":141142,"delay":0,"floatShares":107000000,"shares":109000000,"eps":1.809026,"marketStatus":"交易中","marketStatusCode":2,"change":-0.11,"latestTime":"11-22 12:07:34 EST","open":77.49,"high":77.5,"low":76.8101,"amount":10879785.69374,"amplitude":0.008946,"askPrice":77.04,"askSize":101,"bidPrice":77,"bidSize":21,"shortable":3,"etf":0,"ttmEps":1.809026,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732309200000},"adr":0,"listingDate":766296000000,"adjPreClose":77.12,"adrRate":0,"dividendRate":0.038722,"preHourTrading":{"tag":"盘前","latestPrice":77.12,"preClose":77.12,"latestTime":"08:00 EST","volume":80,"amount":6170.74,"timestamp":1732280421679},"postHourTrading":{"tag":"盘后","latestPrice":77.12,"preClose":77.12,"latestTime":"17:58 EST","volume":75235,"amount":5802123.32,"timestamp":1732229880515},"volumeRatio":0.528355,"impliedVol":0.1908,"impliedVolPercentile":0.2698},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2485448520","title":"Nuvation Bio Inc.盘中异动 大幅上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485448520","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485448520?lang=zh_cn&edition=full","pubTime":"2024-11-22 01:39","pubTimestamp":1732210782,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日01时39分，Nuvation Bio Inc.股票出现波动，股价急速上涨5.04%。截至发稿，该股报2.71美元/股，成交量145.509万股，换手率0.43%，振幅6.20%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112201394298e43fb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112201394298e43fb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVB","DDC","BK4212","ADC","BK4007","BK4231","BK4080"],"gpt_icon":0},{"id":"2484073389","title":"中国生物制药：与礼新医药签署股权投资及战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2484073389","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484073389?lang=zh_cn&edition=full","pubTime":"2024-11-20 06:52","pubTimestamp":1732056752,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","BK1191","BK1521","BK4080","ADC.AU","09939","BK1574","BK7095","BK4231","BK1589","159938","ADC","BK1515","01177"],"gpt_icon":0},{"id":"2484750961","title":"一周内官宣4笔BD交易！双抗新药赛道火爆，跨国药企砸百亿在华“扫货”","url":"https://stock-news.laohu8.com/highlight/detail?id=2484750961","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484750961?lang=zh_cn&edition=full","pubTime":"2024-11-19 14:17","pubTimestamp":1731997033,"startTime":"0","endTime":"0","summary":"本文来源：时代财经 作者：李傲华双抗赛道日渐升温。11月18日，橙帆医药宣布与Avenzo Therapeutics达成一项全球战略合作协议，橙帆医药将授予Avenzo在全球范围内（不包括大中华区）开发、生产和商业化Nectin4/TROP2双特异性抗体偶联药物（ADC），同时保留在大中华区的相关权益。根据约定，橙帆医药可以获得5000万美元的首付...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OGXNPipjng5N0EEVqCMMar7oEn1NEUUoSMX0OgZcn7fE0AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OGXNPipjng5N0EEVqCMMar7oEn1NEUUoSMX0OgZcn7fE0AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241119A052YN00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241119A052YN00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU1057294990.SGD","LU0985320562.USD","SG9999013999.USD","LU0417516571.SGD","LU2461242641.AUD","BK4588","PML","LU1066053197.SGD","09939","LU0289739699.SGD","LU0106261372.USD","GSK","LU1934455863.HKD","BK4080","GSK.UK","LU1061106388.HKD","LU0203347892.USD","LU1116320901.HKD","MRK","LU0053671581.USD","BK4007","SG9999014542.SGD","09926","LU0266013472.USD","SGXZ57979304.SGD","LU1116320737.USD","SG9999015341.SGD","BK4211","LU2112291526.USD","LU2023250504.SGD","IE0002141913.USD","BMS","L","LU0965509010.AUD","IE00BJJMRZ35.SGD","ADC","SG9999001176.SGD","IE00BLSP4239.USD","BK4231","LU1023059063.AUD","BK4534","HR","IE00B1BXHZ80.USD","BK4107","ITT","02162","SG9999001176.USD","LU1934455194.USD","SG9999014559.SGD","PFS"],"gpt_icon":0},{"id":"2483038213","title":"Nuvation Bio Inc.盘中异动 早盘快速跳水5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483038213","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483038213?lang=zh_cn&edition=full","pubTime":"2024-11-15 23:26","pubTimestamp":1731684405,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日23时26分，Nuvation Bio Inc.股票出现异动，股价急速跳水5.23%。截至发稿，该股报2.72美元/股，成交量107.067万股，换手率0.32%，振幅5.92%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为3.27%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115232645971a6e34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115232645971a6e34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADC","NUVB","BK4212","BK4080","BK4007","BK4231","DDC"],"gpt_icon":0},{"id":"2483630193","title":"GSK(GSK.US)ADC疗法3期临床结果积极 延长难治性癌症患者生命","url":"https://stock-news.laohu8.com/highlight/detail?id=2483630193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483630193?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:38","pubTimestamp":1731631089,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，GSK今日宣布，其抗体偶联药物Blenrep在3期临床试验DREAMM-7的预定中期分析中获得了积极结果。该试验评估了Blenrep联合硼替佐米和地塞米松作为复发或难治性多发性骨髓瘤的二线或更晚期治疗的效果。试验达到了总生存期的关键次要终点，显示出Blenrep联合BorDex与标准治疗方案相比，显著降低了患者死亡风险。Blenrep是一种靶向B细胞成熟抗原的抗体偶联药物，由人源化抗BCMA单克隆抗体与细胞毒性载荷auristatin F通过不可切割的连接子结合而成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","GSK.UK","BK4231","ADC","BK4007","LU1829250122.USD","GSK","BK4588","BK4080","BK4585"],"gpt_icon":0},{"id":"2483891626","title":"康宁杰瑞制药-B现涨逾12% HER2双抗ADC皮下注射复方制剂首次公布临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2483891626","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483891626?lang=zh_cn&edition=full","pubTime":"2024-11-14 11:37","pubTimestamp":1731555426,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B早盘上涨12.67%，现报5.07港元，成交额4735.2万港元。11月13日，康宁杰瑞生物制药宣布，HER2双特异性抗体偶联药物（ADC）与PD-L1抑制剂的高浓度皮下注射复方制剂JSKN033的一项临床试验（研究编号：JSKN033-102）符合《优化创新药临床试验审评审批试点工作方案》相关要求，获得上海市药品监督管理局（经药品审评中心（CDE）同意）纳入试点项目，将按要求向CDE提交临床试验申请，预计通过快速通道进行审评审批，以加速启动该项针对晚期恶性肿瘤的Ⅰ/Ⅱ期临床研究。\n\n\r\n            责任编辑：栎树","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/14113745279354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09966","ADC","BK1574","BK4080","BK4231","BK1161"],"gpt_icon":0},{"id":"2483089935","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超12% HER2双抗ADC皮下注射复方制剂首次公布临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2483089935","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483089935?lang=zh_cn&edition=full","pubTime":"2024-11-14 11:11","pubTimestamp":1731553884,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超12%，截至发稿，涨12.67%，报5.07港元，成交额4735.2万港元。此前，康宁杰瑞公布HER2双特异性抗体偶联药物与PD-L1抑制剂的高浓度皮下注射复方制剂JSKN033的首次人体临床研究结果。该研究入选了2024年第39届癌症免疫治疗学会年会最新突破性摘要，于会议期间以壁报形式首次公布。本研究进一步证明了ADC联合免疫治疗的潜力，并支持对JSKN033的持续探索。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4080","BK1161","BK4231","ADC","09966"],"gpt_icon":0},{"id":"2483101860","title":"普米斯作价8亿美元卖身给百欧恩泰 预计2025年第一季完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2483101860","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483101860?lang=zh_cn&edition=full","pubTime":"2024-11-14 09:09","pubTimestamp":1731546588,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司普米斯生物技术公司（简称“普米斯”）今日宣布与BioNTech SE（纳斯达克：BNTX，简称“BioNTech”，百欧恩泰）达成股权收购协议。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20241114/6386717218181253139025099.jpg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20241114/6386717218181253139025099.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.leinews.com/n28214/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4080","ADC","BK4231"],"gpt_icon":0},{"id":"2483629358","title":"医药早参｜阿斯利康撤回Trop2 ADC非鳞状NSCLC上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2483629358","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483629358?lang=zh_cn&edition=full","pubTime":"2024-11-14 08:22","pubTimestamp":1731543747,"startTime":"0","endTime":"0","summary":"每经记者：陈星每经编辑：魏官红｜ 2024年11月14日 星期四 ｜NO.1 阿斯利康撤回Trop2 ADC非鳞状NSCLC的上市申请阿斯利康宣布撤回此前基于TROPION-Lung01三期临床数据递交的治疗非鳞状NSCLC的上市申请，转而递交复发性或转移性EGFR突变NSCLC的后线治疗上市申请。这一上市申请的策略调整是在FDA反馈的基础上做出的。NO.4 卡尔史托斯首批国产内镜影像产品获批上市全球医疗技术公司卡尔史托斯宣布其首批国产内窥镜影像产品已正式获得医疗器械注册证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114082335abbef158&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114082335abbef158&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4080","BK4585","LU2236285917.USD","BK4231","LU2417539215.USD","LU0889565916.HKD","LU2462157665.USD","AZN","BK4007","BK4588","LU0109394709.USD","LU2456880835.USD","LU1829250122.USD","LU0320765992.SGD","BK4568","ADC"],"gpt_icon":0},{"id":"2483420030","title":"阿斯利康(AZN.US)潜在重磅ADC疗法向FDA递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2483420030","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483420030?lang=zh_cn&edition=full","pubTime":"2024-11-13 14:37","pubTimestamp":1731479821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月13日，阿斯利康和第一三共宣布，根据美国FDA的反馈，两家公司已为其联合开发的Trop2靶向抗体偶联药物datopotamab deruxtecan递交生物制品许可申请，寻求该疗法获加速批准，用以治疗携带表皮生长因子受体突变肿瘤的局部晚期或转移性非小细胞肺癌成年患者，这些患者之前曾接受过全身性治疗。同时，两家公司自愿撤回之前向FDA所递交该疗法用以治疗晚期或转移性非鳞状NSCLC患者的BLA。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4568","LU2236285917.USD","LU2462157665.USD","BK4007","ADC","BK4080","AZN","LU0320765992.SGD","LU0109394709.USD","BK4588","LU2456880835.USD","LU2417539215.USD","BK4231","LU0889565916.HKD","BK4585","LU1829250122.USD"],"gpt_icon":0},{"id":"2483001517","title":"康宁杰瑞HER2双抗ADC皮下注射复方制剂JSKN033一项Ⅰ/Ⅱ期临床研究获纳入优化创新药临床试验审评审批试点项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2483001517","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483001517?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:59","pubTimestamp":1731463140,"startTime":"0","endTime":"0","summary":"此次获纳入优化创新药临床试验审评审批试点项目，是对康宁杰瑞差异化创新管线产品的认可，将加速JSKN033在中国的临床开发进程，早日为肿瘤患者带来更安全、有效且依从性更高的治疗选择。关于JSKN033 JSKN033是康宁杰瑞自主研发的全球首个抗体偶联药物和免疫检查点抑制剂的高浓度皮下注射复方制剂, 由JSKN003和恩沃利单抗组成。目前JSKN033正在澳大利亚开展用于治疗HER2表达晚期或转移性实体瘤的Ⅰ/Ⅱ期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4555353_ZH55353_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ADC","09966","BK4512","IE00BFMHRM44.USD","GLW","BK4231","BK1161","BK4585","BK4588","LU0348723411.USD","BK1574","BK4148","BK4080"],"gpt_icon":1},{"id":"2482792515","title":"射频FDA如何使用射频采样ADC来增强测试系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2482792515","media":"电子产品世界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482792515?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:00","pubTimestamp":1731373243,"startTime":"0","endTime":"0","summary":"在本文中，我们将讨论这些缺点，并说明射频全差分放大器  如何帮助您更大限度提高射频采样 ADC 的性能。直流耦合射频采样ADC射频采样ADC接受差分输入，可抑制共模噪声和干扰并改善二阶失真。直流耦合TRF1305射频FDA可利用直流到 6.5GHz 范围的可用大信号带宽来执行单端至差分转换，同时提供增益。图1展示了 TRF1305 射频 FDA 在直流耦合应用中驱动射频采样 ADC 的情况。","market":"hk","thumbnail":"https://k.sinaimg.cn/n/spider20241111/669/w484h185/20241111/5352-ec32e35d167b44f11e33132592e4343b.png/w120h90l50t1c3d.jpg","type":0,"news_type":0,"thumbnails":["https://k.sinaimg.cn/n/spider20241111/669/w484h185/20241111/5352-ec32e35d167b44f11e33132592e4343b.png/w120h90l50t1c3d.jpg"],"rights":{"source":"sina_tech","url":"https://tech.sina.cn/2024-11-11/detail-incvsuti7350836.d.html?vt=4","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}.weibo_user{#sourceStyle#; margin-bottom: 0; display: inline-block;}.weibo_time{#sourceStyle#};","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .j_float_wbro, .j_article_wbreco","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.sina.cn/2024-11-11/detail-incvsuti7350836.d.html?vt=4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_tech","symbols":["BK4231","BK4080","ADC"],"gpt_icon":0},{"id":"2482384237","title":"Nuvation Bio Inc.盘中异动 早盘快速上涨5.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482384237","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482384237?lang=zh_cn&edition=full","pubTime":"2024-11-11 22:32","pubTimestamp":1731335528,"startTime":"0","endTime":"0","summary":"北京时间2024年11月11日22时32分，Nuvation Bio Inc.股票出现异动，股价快速拉升5.90%。截至发稿，该股报3.05美元/股，成交量13.5766万股，换手率0.04%，振幅4.17%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为0.13%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111223208971a5ae8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111223208971a5ae8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4080","NUVB","ADC","BK4007","DDC","BK4212","BK4231"],"gpt_icon":0},{"id":"2482209244","title":"百奥赛图-B(02315)：IDEAYA提名具有同类首创潜力的B7H3/PTK7拓扑异构酶抑制剂有效载荷双特异性ADC(IDE034)作为开发候选药物并行使选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2482209244","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482209244?lang=zh_cn&edition=full","pubTime":"2024-11-11 18:39","pubTimestamp":1731321563,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥赛图-B 发布公告，IDEAYA Biosciences,Inc.，一家致力于发现和开发靶向治疗药物的肿瘤精准医疗公司，已行使选择权，获得百奥赛图具有同类首创潜力的B7H3/PTK7拓扑异构酶抑制剂有效载荷双特异性抗体偶联药物BCG034的全球独家授权，并提名该项目为开发候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","02315","BK4231","BK1161","BK4080"],"gpt_icon":0},{"id":"2482205012","title":"入选LBA！康宁杰瑞HER2双抗ADC皮下注射复方制剂JSKN033最新突破性临床研究结果亮相2024年SITC年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2482205012","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482205012?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:04","pubTimestamp":1731301440,"startTime":"0","endTime":"0","summary":"苏州2024年11月11日 /美通社/ -- 康宁杰瑞生物制药宣布，HER2双特异性抗体偶联药物与PD-L1抑制剂的高浓度皮下注射复方制剂JSKN033的首次人体临床研究结果入选2024年第39届癌症免疫治疗学会年会最新突破性摘要，于会议期间以壁报形式首次公布。本研究进一步证明了ADC联合免疫治疗的潜力，并支持对JSKN033的持续探索。关于JSKN033 JSKN033是康宁杰瑞自主研发的全球首个抗体偶联药物和免疫检查点抑制剂的高浓度皮下注射复方制剂, 由JSKN003和恩沃利单抗组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4552740_ZH52740_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00BFMHRM44.USD","BK4231","09966","BK1574","GLW","SITC","LU0348723411.USD","BK1161","BK4512","BK4080","ADC","BK4148","BK4588","BK4585"],"gpt_icon":0},{"id":"2481017221","title":"Nuvation Bio Inc.盘中异动 急速上涨7.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481017221","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481017221?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:34","pubTimestamp":1731076471,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日22时34分，Nuvation Bio Inc.股票出现波动，股价急速上涨7.82%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822343195bdef97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822343195bdef97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ADC","BK4080","DDC","BK4212","NUVB","BK4231"],"gpt_icon":0},{"id":"2481902031","title":"药明合联赢得2024 World ADC大奖，蝉联\"最佳CDMO冠军\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2481902031","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481902031?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:50","pubTimestamp":1731037800,"startTime":"0","endTime":"0","summary":"中国上海和美国圣地亚哥2024年11月8日 /美通社/ -- 全球领先的专注于提供抗体偶联药物等生物偶联药物端到端CRDMO服务的药明合联，近日在2024 World ADC奖评选中荣膺\"最佳 CDMO冠军\"，这是公司连续第二年荣获该项殊荣。此外，公司已连续三年在World ADC奖中斩获多项荣誉，包括2022年\"最佳CMO亚军\"以及2023年\"最佳CDMO冠军\"。本届World ADC大会上，药明合联还获得了\"最佳CRO\"和\"最佳ADC平台技术\"的提名。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4551571_ZH51571_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1141","ADC","BK4080","02268","BK4139","SG9999014674.SGD","BK4231","CDMO"],"gpt_icon":0},{"id":"2481927939","title":"百利天恒(688506.SH)：BL-M17D1(ADC)用于治疗晚期实体瘤患者的I期临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2481927939","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481927939?lang=zh_cn&edition=full","pubTime":"2024-11-07 17:24","pubTimestamp":1730971469,"startTime":"0","endTime":"0","summary":"智通财金APP讯，百利天恒 发布公告，近日，公司的全资子公司SystImmune,Inc.收到美国食品药品监督管理局的通知，BL-M17D1用于治疗晚期实体瘤患者的I期临床试验申请已获得FDA许可。BL-M17D1是与BL-B16D1出自同一新的小分子技术平台、与BL-B16D1共享同一新的“连接子+毒素”平台的ADC药物，其适应症为晚期实体瘤。包括本次BL-M17D1新获得FDA许可，截至目前，公司共有6个项目已获FDA许可开展临床研究，其他5个分别是：BL-B01D1、BL-M07D1、SI-B001、BL-M05D1、BL-M11D1在美国的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK1576","BK4023","LU1815336091.USD","ADC","BK0239","BK1141","03347","688506","BK1583","LU0757428866.USD","BL","BK4231"],"gpt_icon":0},{"id":"2481859159","title":"Nuvation Bio Inc.盘中异动 早盘股价大涨6.47%报2.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481859159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481859159?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:30","pubTimestamp":1730903425,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时30分，Nuvation Bio Inc.股票出现波动，股价快速拉升6.47%。截至发稿，该股报2.47美元/股，成交量1.8278万股，换手率0.01%，振幅0.00%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622302998e40d31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622302998e40d31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADC","DDC","BK4212","BK4007","NUVB","BK4231","BK4080"],"gpt_icon":0},{"id":"2481552620","title":"FibroGen to Report Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481552620","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481552620?lang=zh_cn&edition=full","pubTime":"2024-11-05 05:05","pubTimestamp":1730754300,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Nov.  04, 2024  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/04/2974423/33525/en/FibroGen-to-Report-Third-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4162","BK4505","BK4139","BK4231","CIA","BK4080","FGEN"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":0.0202},{"period":"1month","weight":0.0268},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.3003},{"period":"1year","weight":0.3419},{"period":"ytd","weight":0.2251}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":-0.004913},{"month":2,"riseRate":0.433333,"avgChangeRate":-0.00204},{"month":3,"riseRate":0.566667,"avgChangeRate":0.014268},{"month":4,"riseRate":0.566667,"avgChangeRate":0.002707},{"month":5,"riseRate":0.516129,"avgChangeRate":0.017098},{"month":6,"riseRate":0.677419,"avgChangeRate":0.011409},{"month":7,"riseRate":0.677419,"avgChangeRate":0.024183},{"month":8,"riseRate":0.451613,"avgChangeRate":0.001804},{"month":9,"riseRate":0.483871,"avgChangeRate":-0.005771},{"month":10,"riseRate":0.548387,"avgChangeRate":-0.001244},{"month":11,"riseRate":0.645161,"avgChangeRate":0.002862},{"month":12,"riseRate":0.5,"avgChangeRate":0.014772}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}